Resources
19 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 10/15/2023 (updated 3/27/2024)
The University of Rochester Recovery Center of Excellence, one of three FORHP-supported Rural Centers of Excellence on Substance Use Disorder, has developed comprehensive training on the treatment of opioid use disorder (OUD) in primary care. This no-cost training prepares providers and staff to deliver evidence-based care to patients. Continuing education credits are available.
Posted 9/8/2023 (updated 3/26/2024)
September 2023 is National Recovery Month and HRSA’s Office of Women’s Health has a toolkit to support organizations and health care providers that care for women living with opioid use disorder (OUD). The toolkit provides strategies to engage women with OUD, care coordination for support, and other resources.
Posted 3/7/2023 (updated 3/27/2024)
n December 2022, Congress eliminated the DATA-Waiver program registration allowing providers to prescribe buprenorphine to treat patients for OUD. The University of Vermont Center on Rural Addiction, a HRSA Rural Center of Excellence on Substance Use Disorders, offers an incentive to help defray previous training costs of $750 to each qualifying provider who obtained a DATA-Waiver. To qualify, providers must be practicing in a HRSA-designated rural county in Vermont, Maine, New Hampshire, or Northern New York.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted 12/21/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration released a notice of proposed rulemaking that would allow certified opioid treatment programs to begin prescribing the drug via audio-only or video-enabled telehealth. See additional information under Policy Updates below. The proposed changes come on top of recent findings by HHS of the positive impact of its revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that removed two longstanding requirements for obtaining a waiver to treat up to 30 patients with buprenorphine: 1) the requirement for specific training, and 2) the need for otherwise eligible clinicians to certify their ability to provide or refer patients for counseling and other services. Rural primary care providers have obtained the DEA waiver at a lower rate than urban clinicians; decreased burden and greater flexibility in the guidelines, along with broader use of telehealth could help close that gap.
Posted 11/16/2022 (updated 3/27/2024)
In this cross-sectional study of 266 Medicaid MCO plans and 39 FFS programs, FFS programs offered more generous MOUD coverage, but a higher percentage of FFS programs imposed PA than MCO plans.
Posted 6/6/2022 (updated 3/27/2024)
Whether an opioid overdose death is unintentional or intentional (i.e., suicide), it can be difficult to disentangle. The suffering and hopelessness associated with addiction often lead to indifference to living or dying and to extreme risk taking. In this presentation, examples were described and presented from an opioid-specific suicide prevention training module that is part of the SafeSide Prevention learning program
Posted 4/20/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration-funded Opioid Response Network (ORN) initiative has launched the Stand Against Stigma (SAS) Challenge. This is an opportunity for those in the healthcare industry to address and dispel stigma related to individuals with substance use disorders through easy, daily activity.
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 10/14/2021 (updated 4/3/2024)
Presenters explained the role of RH in the continuum of care in this exciting and interactive presentation on emerging topics related to integrating social and medical models of recovery. They focused on emerging issues in rural America resulting from the pandemic, its impact on the rates of substance use disorder (SUD), and use of RH. Presenters emphasized funding for the development of RH, the role of partnerships within the recovery ecosystem, and promising practices involving cross-sector collaboration in housing, corrections, treatment, and recovery supports.
Milena Stott, LICSW, SUDP, The Fletcher Group
Erica Walker, CSW, TCADC, The Fletcher Group